Currently out of the existing stock ratings of David Hoang, 30 are a BUY (68.18%), 11 are a HOLD (25%), 3 are a SELL (6.82%).

David Hoang

Work Performance Price Targets & Ratings Chart

Analyst David Hoang, currently employed at DEUTSCHE BANK, carries an average stock price target met ratio of 31.25% that have a potential upside of 20.52% achieved within 174 days. Previously, David Hoang worked at CITI.

David Hoang’s has documented 88 price targets and ratings displayed on 14 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on HRMY, Harmony Biosciences Holdings at 24-Sep-2025.

Wall Street Analyst David Hoang

Analyst best performing recommendations are on LBPH (LONGBOARD PHARMACEUTICALS).
The best stock recommendation documented was for SRPT (SAREPTA THERAPEUTICS) at 12/13/2023. The price target of $113 was fulfilled within 27 days with a profit of $20.89 (22.68%) receiving and performance score of 8.4.

Average potential price target upside

of $49.63 (65.31%) on AXSM (AXSOME THERAPEUTICS).
of $16.71 (62.22%) on LBPH (LONGBOARD PHARMACEUTICALS).
of $10.4 (47.38%) on ALLK (ALLAKOS).

ORTX Orchard Therapeutics PLC ALLK Allakos GOSS Gossamer Bio MLNT Melinta Therapeutics PRVB Provention Bio SRPT Sarepta Therapeutics NBIX Neurocrine Biosciences ACAD ACADIA Pharmaceuticals LBPH Longboard Pharmaceuticals AXSM Axsome Therapeutics DNLI Denali Therapeutics HRMY Harmony Biosciences Holdings XENE Xenon Pharmaceuticals ALKS Alkermes Plc

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Dae Gon Ha (STIFEL)